Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

1.

Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine.

Johansson AS, Owe-Larsson B, Asp L, Kocki T, Adler M, Hetta J, Gardner R, Lundkvist GB, Urbanska EM, Karlsson H.

J Psychiatr Res. 2013 Nov;47(11):1815-23. doi: 10.1016/j.jpsychires.2013.08.008. Epub 2013 Aug 23.

PMID:
24012176
2.

Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation.

Hughes MM, Carballedo A, McLoughlin DM, Amico F, Harkin A, Frodl T, Connor TJ.

Brain Behav Immun. 2012 Aug;26(6):979-87. doi: 10.1016/j.bbi.2012.05.010. Epub 2012 Jun 6.

PMID:
22683764
3.

Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls.

Holtze M, Saetre P, Engberg G, Schwieler L, Werge T, Andreassen OA, Hall H, Terenius L, Agartz I, Jönsson EG, Schalling M, Erhardt S.

J Psychiatry Neurosci. 2012 Jan;37(1):53-7. doi: 10.1503/jpn.100175.

4.

New insight into the antidepressants action: modulation of kynurenine pathway by increasing the kynurenic acid/3-hydroxykynurenine ratio.

Kocki T, Wnuk S, Kloc R, Kocki J, Owe-Larsson B, Urbanska EM.

J Neural Transm (Vienna). 2012 Feb;119(2):235-43. doi: 10.1007/s00702-011-0668-8. Epub 2011 Jun 10.

PMID:
21660485
5.

The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression.

Lavebratt C, Olsson S, Backlund L, Frisén L, Sellgren C, Priebe L, Nikamo P, Träskman-Bendz L, Cichon S, Vawter MP, Osby U, Engberg G, Landén M, Erhardt S, Schalling M.

Mol Psychiatry. 2014 Mar;19(3):334-41. doi: 10.1038/mp.2013.11. Epub 2013 Mar 5.

6.

Correlations of Kynurenic Acid, 3-Hydroxykynurenine, sIL-2R, IFN-α, and IL-4 with Clinical Symptoms During Acute Relapse of Schizophrenia.

Szymona K, Zdzisińska B, Karakuła-Juchnowicz H, Kocki T, Kandefer-Szerszeń M, Flis M, Rosa W, Urbańska EM.

Neurotox Res. 2017 Mar 8. doi: 10.1007/s12640-017-9714-0. [Epub ahead of print]

PMID:
28275903
7.
8.

Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse.

Saito K, Markey SP, Heyes MP.

Neuroscience. 1992 Nov;51(1):25-39.

PMID:
1465184
9.

Association study between kynurenine 3-monooxygenase gene and schizophrenia in the Japanese population.

Aoyama N, Takahashi N, Saito S, Maeno N, Ishihara R, Ji X, Miura H, Ikeda M, Suzuki T, Kitajima T, Yamanouchi Y, Kinoshita Y, Yoshida K, Iwata N, Inada T, Ozaki N.

Genes Brain Behav. 2006 Jun;5(4):364-8.

10.

The kynurenine pathway in schizophrenia and bipolar disorder.

Erhardt S, Schwieler L, Imbeault S, Engberg G.

Neuropharmacology. 2017 Jan;112(Pt B):297-306. doi: 10.1016/j.neuropharm.2016.05.020. Epub 2016 May 28. Review.

PMID:
27245499
11.

Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients.

Myint AM, Schwarz MJ, Verkerk R, Mueller HH, Zach J, Scharpé S, Steinbusch HW, Leonard BE, Kim YK.

Brain Behav Immun. 2011 Nov;25(8):1576-81. doi: 10.1016/j.bbi.2011.05.005. Epub 2011 May 17.

PMID:
21620952
12.

Two complex genotypes relevant to the kynurenine pathway and melanotropin function show association with schizophrenia and bipolar disorder.

Miller CL, Murakami P, Ruczinski I, Ross RG, Sinkus M, Sullivan B, Leonard S.

Schizophr Res. 2009 Sep;113(2-3):259-67. doi: 10.1016/j.schres.2009.05.014. Epub 2009 Jun 6.

13.

Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia.

Notarangelo FM, Wilson EH, Horning KJ, Thomas MA, Harris TH, Fang Q, Hunter CA, Schwarcz R.

Schizophr Res. 2014 Jan;152(1):261-7. doi: 10.1016/j.schres.2013.11.011. Epub 2013 Dec 15.

14.

Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder.

Savitz J, Dantzer R, Wurfel BE, Victor TA, Ford BN, Bodurka J, Bellgowan PS, Teague TK, Drevets WC.

Psychoneuroendocrinology. 2015 Feb;52:200-11. doi: 10.1016/j.psyneuen.2014.11.015. Epub 2014 Nov 24.

15.

Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: a role for IFN-gamma?

Connor TJ, Starr N, O'Sullivan JB, Harkin A.

Neurosci Lett. 2008 Aug 15;441(1):29-34. doi: 10.1016/j.neulet.2008.06.007. Epub 2008 Jun 7.

PMID:
18584961
16.

On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo.

Amori L, Guidetti P, Pellicciari R, Kajii Y, Schwarcz R.

J Neurochem. 2009 Apr;109(2):316-25. doi: 10.1111/j.1471-4159.2009.05893.x. Epub 2009 Feb 6.

17.

Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia--significance for activation of the kynurenine pathway.

Schwieler L, Larsson MK, Skogh E, Kegel ME, Orhan F, Abdelmoaty S, Finn A, Bhat M, Samuelsson M, Lundberg K, Dahl ML, Sellgren C, Schuppe-Koistinen I, Svensson C, Erhardt S, Engberg G.

J Psychiatry Neurosci. 2015 Mar;40(2):126-33.

18.

Kynurenic acid and 3-hydroxykynurenine production from D-kynurenine in mice.

Wang XD, Notarangelo FM, Wang JZ, Schwarcz R.

Brain Res. 2012 May 21;1455:1-9. doi: 10.1016/j.brainres.2012.03.026. Epub 2012 Mar 17.

19.
20.

Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications.

Ceresoli-Borroni G, Guidetti P, Amori L, Pellicciari R, Schwarcz R.

J Neurosci Res. 2007 Mar;85(4):845-54.

PMID:
17279543

Supplemental Content

Support Center